Close Menu

NEW YORK – Oppenheimer has initiated coverage of MDxHealth with an Outperform rating and a price target of €2 per share.

In a note to investors on Monday, analyst Kevin DeGeeter cited the investment bank's expectation that the US Centers for Medicare and Medicaid Services will likely issue a positive Local Coverage Determination in 2021 for the use of the company's SelectMDx prostate cancer diagnostic in men considering a biopsy for prostate cancer detection.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.